Low dose Canagliflozin effectively reduces hs-CRP and CR markers in diabetes

Vishal Gupta from Mumbai, India, and colleagues compared the efficiency of both different doses of Canagliflozin (C1) 100mg & Canagliflozin (C3) 300mg on highly reactive sensitive C reactive protein (hs-CRP) and other cardio-renal (CR) biomarkers. 

For the study, the researches identified a cohort of 190 patients with type 2 diabetes mellitus (T2DM) aged 18-75 years, irrespective of baseline A1c, receiving SGLTi C1 or C3. They performed a propensity score 1:1 matching for both the groups with variables that could affect treatment outcomes and minimize confounding. The patients were evaluated every 2-3months for CR biomarkers (body mass index (BMI), A1c, systolic (S) BP, diastolic (D) BP, Lipid profile (TC, LDL, TG, HDL), Hs-CRP, creatinine, eGFR, and urinary albumin/creatinine ratio {UACR}). NT-ProBNP was evaluated at 12 months. 44 patients were identified in the C1 group and 44 in the C3 group.' 

Key findings of the study include:

• Reduction in C1 group (baseline to 12m): there was a S reduction in hs-CRP, A1c, BMI, SBP, DBP, TC, TG, LDL.

• Reduction in C3 group (baseline to 12m): there was a S reduction in hs-CRP, A1c, BMI, SBP, DBP, TC, LDL.

• Difference between C1 and C3 at 12m: There was no difference in biomarkers between both the groups, included Lipid profile, SBP and DBP.

"Both Canagliflozin 100mg and Canagliflozin 300mg has similar efficiency for the reduction of hs-CRP and CR markers in type 2 diabetes patients," concluded the authors.

For further reference follow the link: https://doi.org/10.2337/db20-2219-PUB